药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Spectinomycin
Irbesartan
Midomafetamine may decrease the antihypertensive activities of Irbesartan.
Spectinomycin
Trichlormethiazide
Midomafetamine may decrease the antihypertensive activities of Trichlormethiazide.
Almotriptan
Oliceridine
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when gamma-Hydroxybutyric acid is combined with Oliceridine.
Almotriptan
Lasmiditan
The risk or severity of adverse effects can be increased when gamma-Hydroxybutyric acid is combined with Lasmiditan.
Almotriptan
Cyclobenzaprine
The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with gamma-Hydroxybutyric acid.
Almotriptan
Esketamine
The risk or severity of adverse effects can be increased when gamma-Hydroxybutyric acid is combined with Esketamine.
Almotriptan
Medical Cannabis
The therapeutic efficacy of gamma-Hydroxybutyric acid can be increased when used in combination with Medical Cannabis.
Almotriptan
Xenon
The therapeutic efficacy of Xenon can be increased when used in combination with gamma-Hydroxybutyric acid.
Almotriptan
Enibomal
The therapeutic efficacy of Enibomal can be increased when used in combination with gamma-Hydroxybutyric acid.
Almotriptan
Chloroform
The therapeutic efficacy of Chloroform can be increased when used in combination with gamma-Hydroxybutyric acid.
Almotriptan
Tetracaine
The therapeutic efficacy of Tetracaine can be increased when used in combination with gamma-Hydroxybutyric acid.
Almotriptan
Cannabinol
The risk or severity of adverse effects can be increased when Cannabinol is combined with gamma-Hydroxybutyric acid.
Almotriptan
Palmidrol
The risk or severity of adverse effects can be increased when Palmidrol is combined with gamma-Hydroxybutyric acid.
Almotriptan
Nabiximols
The risk or severity of adverse effects can be increased when Nabiximols is combined with gamma-Hydroxybutyric acid.
Almotriptan
WIN 55212-2
The risk or severity of adverse effects can be increased when WIN 55212-2 is combined with gamma-Hydroxybutyric acid.
Almotriptan
Surinabant
The risk or severity of adverse effects can be increased when Surinabant is combined with gamma-Hydroxybutyric acid.
Almotriptan
Ibipinabant
The risk or severity of adverse effects can be increased when Ibipinabant is combined with gamma-Hydroxybutyric acid.
Almotriptan
Ajulemic acid
The risk or severity of adverse effects can be increased when Ajulemic acid is combined with gamma-Hydroxybutyric acid.
Almotriptan
GW842166
The risk or severity of adverse effects can be increased when GW842166 is combined with gamma-Hydroxybutyric acid.
Almotriptan
Cannabidiol
The risk or severity of adverse effects can be increased when Cannabidiol is combined with gamma-Hydroxybutyric acid.